Research

Clinical trials

Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.

Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.

Recruiting and upcoming studies

The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.

Showing 1–12 of 208 trials

RecruitingAL (light chain)

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma (opens on ClinicalTrials.gov)

The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and…

Study
Interventional (treatment)
Phase
Phase 1
Sponsor
Janssen Research & Development, LLC

Recruiting in: AustraliaIsraelNetherlandsSpain+1

NCT06768489Updated 25 September 2026

RecruitingATTR (transthyretin)

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis (opens on ClinicalTrials.gov)

Transthyretin (TTR) is a protein made by the liver that helps transport thyroid hormone and vitamin A in the blood. In some people, this…

Study
Interventional (treatment)
Phase
Phase 4
Sponsor
Bayer

Recruiting in: AustriaBelgiumGermanyItaly+1

NCT07298044Updated 25 September 2026

RecruitingAL (light chain)

BE.Amycon Biobank & Data Registry UZ Leuven (opens on ClinicalTrials.gov)

The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank "BE.Amycon biobank" for…

Study
Observational (registry, imaging)
Sponsor
Universitaire Ziekenhuizen KU Leuven

Recruiting in: Belgium

NCT07172243Updated 25 September 2026

Not yet recruitingATTR (transthyretin)

Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor (opens on ClinicalTrials.gov)

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid in the heart muscle. This…

Study
Observational (registry, imaging)
Sponsor
Bayer

Recruiting in: AustriaGermanyItaly

NCT07557147Updated 24 September 2026

Not yet recruitingATTR (transthyretin)

[18F]FIDT-10b PET Imaging in Cardiac Amyloidosis (opens on ClinicalTrials.gov)

This is a first in human study that will assess the safety, pharmacokinetics, biodistribution and diagnostic performance of [18F]FIDT-10b (fluorine-18 labeled FIDT-10b), a positron…

Study
Interventional (treatment)
Phase
Phase 1
Sponsor
Peking Union Medical College Hospital

Recruiting in: China

NCT07835880Updated 23 September 2026

Not yet recruitingNot specified

Individualized Exercise Training in Cardiac Amyloidosis (opens on ClinicalTrials.gov)

Numerous clinical trials have demonstrated that transthyretin (TTR)-directed medical therapies can reduce the rate of functional decline in patients with transthyretin cardiac amyloidosis (ATTR-CM).…

Study
Interventional (treatment)
Sponsor
Oregon Health and Science University

No study locations listed yet

NCT07835867Updated 23 September 2026

RecruitingATTR (transthyretin)

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis (opens on ClinicalTrials.gov)

This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with…

Study
Interventional (treatment)
Phase
Phase 3
Sponsor
Novo Nordisk A/S

Recruiting in: ArgentinaAustraliaBelgiumBrazil+16

NCT07207811Updated 22 September 2026

This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 25 September 2026. clinicaltrials.gov

Not sure where to start?

Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.